Guardant Health Inc(GH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.5 | Insider Own | 4.05% | Shs Outstand | 133.6M | Perf Week | 6.61% |
| Market Cap | 22.69B | Forward P/E | - | EPS next Y | 34.65% | Insider Trans | -14.22% | Shs Float | 128.8M | Perf Month | -4.18% |
| Enterprise Value | 23.33B | PEG | - | EPS next Q | -0.75 | Inst Own | 101.23% | Short Float | 9.25% | Perf Quarter | 16.23% |
| Income | -0.45B | P/S | 19.18 | EPS this Y | 2.19% | Inst Trans | -1.76% | Short Ratio | 6.12 | Perf Half Y | 90.17% |
| Sales | 1.18B | P/B | - | EPS next 5Y | 57.16% | ROA | -27.95% | Short Interest | 11.92M | Perf YTD | 65.54% |
| Book/sh | -1.67 | P/C | 21.54 | EPS past 3/5Y | 19.67% -4.99% | ROE | - | 52W High | -11.5% ($191.05) | Perf Year | 143.81% |
| Cash/sh | 7.85 | P/FCF | - | Sales past 3/5Y | 29.75% 27.92% | ROIC | -31.35% | 52W Low | 153.91% ($66.59) | Perf 3Y | 550.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -4.6% | Gross Margin | 65.01% | Volatility(W/M) | 5.83% 5.11% | Perf 5Y | 54.62% |
| Dividend TTM | - | EV/Sales | 19.72 | Sales Y/Y TTM | 42.74% | Oper. Margin | -39.7% | ATR (14) | 8.67 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.71 | EPS Q/Q | -12.34% | Profit Margin | -38.33% | RSI (14) | 51.84 | Recom | 1.41 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.03 | Sales Q/Q | 44.33% | SMA20 | 0.14% ($168.84) | Beta | 1.69 | Target Price | $205.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | 0.67% ($167.95) | Rel Volume | 0.86 | Prev Close | $162.94 |
| Employees | 2506 | LT Debt/Eq | - | EPS/Sales Surpr. | -18.14% 6.6% | SMA200 | 31.36% ($128.71) | Avg Volume(3M) | 1.95M | Price | $169.08 |
| IPO | 2018/10/4 | Option/Short | Yes/Yes | Trades | 24406 | Volume | 1,669,827 | Change | 3.77% |
🧬 A precision diagnostics company that offers blood-based cancer genomic testing. Its core technology is liquid biopsy, which analyzes cancer-related genetic mutations from blood samples, and it provides cancer diagnostics to help guide treatment choices as well as early cancer screening tests. It is one of the leading companies in the liquid biopsy-based cancer diagnostics space.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
Next earnings report: November 5
10 days to go.
GH has a sound balance sheet but weak earning power
Of every $100 in sales, $39.70 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,918. Peers typically go for $658.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +54.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 101.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HELX Franklin Genomic Advancements ETF 0.09% 
EKG First Trust Nasdaq Lux Digital Health Solutions ETF 0.06% 
GNOM Global X Genomics & Biotechnology ETF 0.06% 
LFSC F/m Emerald Life Sciences Innovation ETF 0.06% 
GDOC Goldman Sachs Future Health Care Equity ETF 0.05% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
RSP Invesco S&P 500 Equal Weight ETF 100.1B 
FBND Fidelity Total Bond ETF 28.4B 
USHY iShares Broad USD High Yield Corporate Bond ETF 25.8B 
SDY State Street SPDR S&P Dividend ETF 22.2B 
DGRW WisdomTree U.S. Quality Dividend Growth Fund 17.1B It ranks #12 of 44 in the industry
Based on market cap of $23B.
DGX#10 Quest Diagnostics Inc $27B PER 24.1 
LH#11 Labcorp Holdings Inc $27B PER 27.2 GH#12 Guardant Health Inc $23B PER - 
MEDP#13 Medpace Holdings Inc $19B PER 37.1 
RVTY#14 Revvity Inc $18B PER 75.4 
FAQ
What kind of company is GH?
GH belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of GH?
The market cap of GH is approximately $22.7B, ranking 556 within its sector.
What is the 52-week high and low for GH?
GH has recorded a 52-week high of $191.05 and a low of $66.59.
